Overview
Welcome to Dwaey, specifically on JANUVIA 25 Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Sitagliptin (as monohydrate phosphate).
JANUVIA 25 is available in the market in concentration 25mg/Tablet and in the form of Tablets/Film-coated.
MERCK SHARP & DOHME LIMITED is the producer of JANUVIA 25 and it is imported from UK, The most popular alternatives of JANUVIA 25 are listed downward .
Sitagliptin inhibits dipeptidyl peptidase IV (DPP-IV), resulting in prolonged active incretin levels. Incretin hormones increases insulin synthesis and release from pancreatic ?-cells and reduces glucagon secretion from pancreatic ?-cells. Reduced glucagon secretion leads to decreased hepatic glucose production.
Patient w/ type 1 diabetes, history of angioedema. Not intended for the treatment of diabetic ketoacidosis. Moderate and severe renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor glycosylated Hb (HbA1c), serum glucose. Assess renal function prior to initiation of therapy and periodically thereafter. Lactation: Not known whether excreted in breast milk: use caution
Hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome can occur. Type 1 diabetes. Diabetic ketoacidosis.
Pregnancy category: B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.
Sitagliptin (as monohydrate phosphate)
Sitagliptin (as monohydrate phosphate)
Sitagliptin (as monohydrate phosphate)